Viral Production Core Facility

在2023财年，病毒生产核心设施启动了44个项目，生产63个AAV和慢病毒载体；其中50%的项目用于NINDS实验室。其他项目是针对NIMH、NCI和NIAAA的实验室。这些具有特殊科学意义的多机构项目包括：1)为NINDS实验室设计和构建能够表达来自同一病毒构建物的蛋白质和shRNA的AAV；2)为NIAAA实验室生产用于逆行靶向投射神经元的第二代狂犬病病毒载体；3)为NIMH实验室设计和构建表达AAVs的INTRSECT核心；4)为NCI实验室生产用于筛选CAR-T构建物的慢病毒载体。向NINDS/NIH实验室提供的核心设施，除了基本的病毒载体生产外，还包括就病毒载体的使用进行咨询，并协助研究和设计病毒载体特定靶标的项目。

In FY 2023, the Viral Production Core Facility initiated 44 projects for producing 63 AAV and lentivirus viral vectors; 50% of the projects were for NINDS labs. The other projects were for laboratories in NIMH, NCI, and NIAAA. These multi-institutional projects of particular scientific significance included: 1) design and construction by the core of an AAV capable of expressing protein and shRNA from the same viral construct for an NINDS laboratory; 2) production of a second-generation rabies viral vector for retrograde targeting of projection neurons for a laboratory in NIAAA; 3) design and construction by the core of INTRSECT expressing AAVs for an NIMH laboratory; 4) production of lentiviral vectors for screening CAR-T constructs for labs in NCI. The service the core facility provided to NINDS/NIH labs beyond essential viral vector production also included consultations on the use of viral vectors and assistance in research and design of projects for specific targeting by viral vectors.